3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
55
Neoplasms, Plasma Cell
22
Central Nervous System Neoplasms
10
Prostatic Neoplasms
9
Glioblastoma
9
Recurrence
8
Melanoma
8
Brain Neoplasms
8
Neoplasms
7
Gliosarcoma
7
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
6
Leukemia
6
Carcinoma, Hepatocellular
6
Waldenstrom Macroglobulinemia
5
Myeloproliferative Disorders
5
Lung Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Glioma
5
Colorectal Neoplasms
5
Myelodysplastic-Myeloproliferative Diseases
4
Myelodysplastic Syndromes
4
Lymphoma
4
Liver Neoplasms
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Kidney Neoplasms
4
Carcinoma, Renal Cell
4
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myelomonocytic, Chronic
3
Interventions
Bevacizumab
10
Magnetic Resonance Spectroscopy
9
Temozolomide
8
Cyclophosphamide
8
Etoposide
7
X-Rays
6
Phantoms, Imaging
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Cisplatin
5
Radiotherapy
4
Irinotecan
4
Filgrastim
4
Carboplatin
4
Biopsy
4
Erlotinib Hydrochloride
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
sargramostim
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Vincristine
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ependymoma
×
Thalidomide
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled